Interinvest acquires common shares of Amorfix Life Sciences

This press release is being disseminated as required by National Instrument 62-103 The Early Warning System and Related Take Over Bids and Insider Reporting Issues in connection with the filing of an early warning report (the "Early Warning Report") regarding the acquisition of securities of Amorfix Life Sciences Ltd. ("Amorfix") by the Interinvest Group of Companies ("Interinvest") of Boston, Massachusetts.

On August 16, 2010, Interinvest reported that it had acquired direction or control through open market purchases of a total of 4,862,550 common shares of Amorfix representing 10.0% of the issued and outstanding common shares. Dr. Hans Black, the Chairman of Interinvest is also a director of Amorfix. Both he and Mr. Michael R. Sonnenreich, also a director of Amorfix, hold common shares of Amorfix that are included in the 10.0% as they are held within Interinvest accounts.

"We appreciate this strong endorsement of Amorfix by Interinvest and our directors who share our vision and confidence in our product pipeline and its future prospects," said Dr. Robert Gundel, Chief Executive Officer of Amorfix.

The common shares were acquired for investment purposes and Interinvest may increase or decrease its direction or control depending on market or other conditions.

Source:

AMORFIX LIFE SCIENCES LTD.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.